Levocarnitine for anemia in dialysis patients
Treatments studied
Part of Blood & lymphatic, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests whether a supplement called levocarnitine can help reduce the amount of anemia medicine (ESA) you need. It is for people on dialysis who have anemia from kidney disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 20 and 60 years old.
- You have been on regular dialysis (three times a week) for at least six months.
- You have anemia related to kidney disease.
- You are not currently taking any carnitine supplements (like L-carnitine).
- You are not taking immunosuppressants, steroids, or antibiotics.
- You have not had a blood transfusion in the past six months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether spironolactone can help treat anemia in children aged 6-18 who are on hemodialysis. It may improve their response to current anemia treatments.
This trial tests whether taking carnitine supplements by mouth can help people who have both heart failure and early-to-moderate kidney problems. It's an early-phase study to see if the supplement is safe and works for this group.
This early-phase study tests whether levocarnitine can reduce liver injury from a chemotherapy medicine called asparaginase in people with high-risk acute lymphoblastic leukemia (ALL). If you’re eligible, you would take levocarnitine by mouth alongside your planned standard cancer treatment to see if the liver stays healthier.
This study tests whether adding L-carnitine (a naturally occurring compound) to standard care helps people with serious liver disease who are in the intensive care unit. L-carnitine may help the body use energy better and reduce complications from liver failure.
This trial tests a new oral medicine (AND017) for people on dialysis who have anemia (low red blood cells). It may help reduce the need for injections of standard anemia medicines.
This trial tests whether taking an oral pill three times a week (vadadustat) works as well as injections (Epogen) to treat anemia—low red blood cells—in people on dialysis. If it works, a pill might be easier and more convenient than injections.
Hear when a new Anemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.